Osteopathic Manipulative Therapy for Long COVID Symptoms

This study is looking at how Osteopathic Manipulative Therapy (OMT) might help people with Long COVID (also known as Post-Acute Sequelae of COVID-19 or PASC). OMT is a hands-on treatment that can help with body pain and movement. Researchers want to see if a specific OMT protocol, which previously helped with smell loss in Long COVID, can also improve other Long COVID symptoms. They also want to know if two OMT treatments are more effective than one. You might be able to join if you are 18 or older, have had a positive COVID-19 test at least 6 weeks ago, and are still experiencing at least one Long COVID symptom that affects your daily life. The study will measure symptom improvement using a survey called The Symptom Burden Questionnaire™ for Long COVID (SBQ™-LC). The study is currently unclear on its recruitment status and plans to enroll 20 participants.

Study design
This interventional study plans to enroll 20 participants. It will compare a specific Long-COVID OMT protocol to a different OMT protocol.
What's involved
Participants will complete a digital survey and receive an OMT treatment in Week 1. In Week 2, they will complete another digital survey and receive the Long-COVID OMT treatment.
Compensation
Not stated in the trial record.
Follow-up
Participants will complete surveys at Week 1, Week 2, Week 3, and a final survey at Week 8 after enrollment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06883513

Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID

Recruiting
NAAges 18+InterventionalTreatment
University of Louisville
~20 participants
Updated 2025-03-19 on ClinicalTrials.gov
What's tested:Osteopathic Manipulative Therapy Long-COVID protocolOsteopathic Manipulative Therapy NOT Long-COVID treatment protocol

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The Symptom Burden Questionnaire™ for Long COVID (SBQ™-LC)
Measured over On arrival for baseline before any treatment (week 1). On arrival for 2nd treatment (week 2). 7 days after 2nd treatment (week 3). Final Survey on week 8 of post-enrollment
Long-COVID
PASC
Long COVID Syndrome

NCT06883513

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Louisville Outpatient Care Center

    Louisville, Kentuckystudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Darryl Kaelin, MD, Medical Doctorate (US) · PRINCIPAL_INVESTIGATOR · University of Louisville School of Medicine Chair of PM&R Division of the Department of Neurological Surgery
Michael E Stenta, DO, Doctor of Osteopathic Medicine
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

\- Individuals must claim they have had a prior positive SARS-CoV-2 test at least 6-weeks before the consenting process to proceed with the study
Individuals must claim they have at least one of the following symptoms greater than 6-weeks post infection that is affecting their daily life(these symptoms correlate with the SBQ™-LC):
Shortness of breath or Difficulty Breathing
Difficulty with Movement (balance or tremor)
Muscle Pain or stiffness
Changes in sexual desire
Worsening Generalized Pain
Difficulty with Sleep
Changes in Mood (anxiety or depression)
Changes in Erectile function (Biological males only)
Palpations (irregular heart beats)
Altered Taste
Changes in your Hair
Changes in urination
Dizziness
Altered Smell
Changes in Skin
Changes in bowels
Fatigue
Indigestion
Dry or irritated eyes
Changes in sweating
Difficulty with Cognition (memory or thinking)
Stomach Pain
Changes in menstruation (Biological females only)
Chills or shivering

Exclusion

If anyone denies they have any of the above symptoms before consent, they will be excluded from the trial
They will also be excluded from the trial if they have suffered any fractured bones in the last 3 months (this will further decrease risk to the patient as the patient will be moved by the physician during the treatment protocol)
Participants who are enrolled in other Long-COVID trials that have an intervention during their participation in this trial will be excluded. However, if they have a history of enrollment in a long-covid trial that has no interventions during this trial, they will not be excluded based on their history of acquiring experimental treatment.
  • The Symptom Burden Questionnaire™ for Long COVID (SBQ™-LC)On arrival for baseline before any treatment (week 1). On arrival for 2nd treatment (week 2). 7 days after 2nd treatment (week 3). Final Survey on week 8 of post-enrollment

    The Symptom Burden Questionnaire™ for Long COVID (SBQ™-LC) is a validated tool generated to assess for Long-COVID symptom burden generated by the University of Birmingham in the UK. The SBQ™-LC assesses 123 different symptoms of Long COVID. All items use the recall period "In the last 7 days..." and are scored according to one of the following: 1. symptom presence (Yes/No); 2. symptom frequency (0 = Never to 3 = Always); 3. symptom severity (0 = None to 3 = Severe); 4. or Interference in daily life (0 = Not at all to 3 = Severely). The SBQ™-LC has a Flesch-Kincaid Reading Grade level score of 5.33 suggesting it would be understood by a person with a 6th grade reading level according to the American education system. The SBQ™-LC's SMOG Index score of 8.27 means it should be understood by 93% of UK adults.(8-10) Higher scores suggest worsening symptom severity. Maximum raw score depends on which independent scale within the tool is measured. Ranges from 5-38 depending